PRL-3 Inhibitor

PRL-3 Inhibitor

Catalog Number:
L002372922APE
Mfr. No.:
APE-C3996
Price:
$279
  • Size:
    Quantity:
    Add to Cart:
      • Overview
        • Please contact us at for specific academic pricing.

          Background

          IC50: 900 nM: blocks human phosphatase of regenerating liver 3 (PRL-3) in vitro.PRL-3 inhibitor, a cell-permeable benzylidene rhodamine compound, potently dampens PRL-3 and inhibits other phosphatases with minimal activity. It has been demonstrated that PRL-3 inhibitor can be used as therapeutics for the treatment of cancer. PRL-3 is a member of the regenerating liver family tyrosine phosphatases and plays vital roles in cell proliferation, migration, invasion, and motility, and thus leads to cancer metastasis.In vitro: PRL-3 inhibitor, in a dose-dependent fashion, blocked the dephosphorylation of DiFMUP by PRL-3 and strongly suppressed the activity of PRL-3 phosphatase in PRL-3 overexpressing DLD-1 colon tumor cells [DLD-1 (PRL-3)]. Also, PRL-3 inhibitor dose-dependently blocked the migration of DLD-1 (PRL-3) cells, however, it did not inhibit the proliferation of DLD-1(PRL-3) cells, suggesting that PRL-3 inhibitor significantly blocked cell immigration and invasion without cytotoxicity [1].In vivo: Up to now, in vivo study of PRL-3 Inhibitor is still in the development stage.

      • Properties
        • Alternative Name
          BR-1,P0108,Phosphatase of Regenerating Liver 3 Inhibitor,PTP4A3 Inhibitor; 5-[[5-bromo-2-[(2-bromophenyl)methoxy]phenyl]methylene]-2-thioxo-4-thiazolidinone
          CAS Number
          893449-38-2
          Molecular Formula
          C17H11Br2NO2S2
          Molecular Weight
          485.2
          Appearance
          A crystalline solid
          Purity
          98.00%
          Solubility
          ≤16mg/ml in DMSO;16mg/ml in dimethyl formamide
          Storage
          Store at -80°C

          * For Research Use Only

    Note: If you don't receive our verification email, do the following:

    Copyright © Amerigo Scientific. All rights reserved.